ImPact Biotech Announces Phase 3 Study Data at SUO 2025
TEL AVIV, Israel — ImPact Biotech, a clinical-stage biotechnology company, has made significant strides in advancing Padeliporfin vascular targeted photodynamic (VTP) therapy, aimed at treating a variety of solid tumors. The company has recently shared updated interim results from its ongoing Phase 3 ENLIGHTED study. This data is set to be presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025), scheduled for early December.
Details of the Presentation
At the SUO 2025 conference, Dr. Vitaly Margulis, a key figure in urologic oncology from the University of Texas Southwestern Medical Center, will present an abstract. This abstract encompasses critical findings from the therapy's effectiveness and safety, focusing on patients suffering from low-grade upper tract urothelial carcinoma (UTUC). The presentation is particularly anticipated due to the promising nature of the results.
Poster and Session Information
Poster Title: ENLIGHTED Phase 3 study: Efficacy and Safety of Padeliporfin VTP for Low-grade Upper Tract Urothelial Cancer
Presenter: Dr. Vitaly Margulis
Poster Number: 166
Session Title: SUO Top Abstract Tour
Session Date & Time: December 4, 2025, 4:30 PM MST
Recent Data Highlights from ENLIGHTED
The company has recently featured further data at the 17th European Multidisciplinary Congress on Urological Cancers (EMUC 2025). This showcased the interim results of the ENLIGHTED trial, emphasizing the efficacy of the VTP therapy. The interim analysis reported a notable complete response rate of 73%, indicating a strong safety profile as well. These data were derived from 50% of the target enrollment, reflecting substantial engagement in the trial.
ImPact Biotech’s Vision and Research
ImPact Biotech is dedicated to the development of Padeliporfin VTP, which is recognized for its innovative approach to selectively ablate solid tumors. The therapy integrates a minimal invasion strategy aimed at enhancing patient outcomes. The work being done not only aims to improve treatment for UTUC but also extends to pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC).
Commitment to Advancement in Oncology
The ongoing and planned studies under the ImPact Biotech umbrella represent a commitment to addressing some of the most challenging cancers today. With a rich background of partnerships, including collaborations with esteemed institutions, ImPact Biotech is positioned at the forefront of clinical advancements and innovation.
Contact Information
Global Head of Business Development:
Guy Schmidt
guy.schmidt@impactbiotech.com
Frequently Asked Questions
What is the ENLIGHTED study about?
The ENLIGHTED study examines the efficacy and safety of Padeliporfin VTP therapy in treating low-grade upper tract urothelial carcinoma.
Who is presenting the data at SUO 2025?
Dr. Vitaly Margulis from the University of Texas Southwestern Medical Center will present the findings.
What was the response rate reported in the interim analysis?
The interim results showed a complete response rate of 73% among evaluable patients.
What are the future plans for Padeliporfin VTP?
Future studies are planned to explore its effectiveness in high-grade UTUC, pancreatic cancer, and non-small cell lung cancer.
How can I learn more about ImPact Biotech?
For more information, visit their official website at www.impactbiotech.com.
